Ayman Chit, PhD, discusses rising vaccine confusion in pediatric care

Rising confusion around childhood immunizations is being driven largely by the rapid spread of misinformation and disinformation, particularly through social media, alongside broader technological and sociopolitical shifts. According to Ayman Chit, PhD, head of Vaccines Medical, North America, at Sanofi, these forces have fundamentally altered how families encounter and interpret vaccine information.

Instead of relying primarily on clinician guidance, many caregivers now arrive at pediatric visits having already engaged with a wide range of often conflicting content online. This has led to increased uncertainty and more complex, time-intensive discussions in clinical settings. Pediatricians, who previously could expect general acceptance of vaccine recommendations, are now facing a significantly greater communication burden, with families asking numerous and sometimes unconventional questions shaped by online narratives.

At the same time, the policy landscape for immunizations in the United States has changed recently, contributing to temporary confusion in clinical practice. Although alignment around guidance from the American Academy of Pediatrics has helped stabilize recommendations, the transition period created friction for providers navigating evolving expectations. While many health systems have now recalibrated, the earlier uncertainty highlighted gaps between national policy updates and real-world implementation, with implications for workflow, consistency in messaging, and patient care.

Despite public concerns, vaccine safety monitoring systems remain robust and have, in fact, strengthened. The United States maintains one of the most advanced surveillance infrastructures globally, supported by large-scale digital health data and standardized protocols for detecting and evaluating adverse events.

These systems involve coordinated efforts among regulators, manufacturers, researchers, and public health agencies, and operate continuously alongside the rigorous prelicensure trials required for vaccine approval. However, the complexity and scale of these systems can be misunderstood by both clinicians and families, contributing to ongoing skepticism.

Improving vaccine confidence, Chit suggests, begins with ensuring that pediatricians themselves are well informed and confident in the safety monitoring framework. Clinicians who understand and trust the system are better equipped to communicate its rigor and transparency effectively. This may require renewed engagement with educational resources and professional guidelines, particularly given that high baseline trust in prior years meant less emphasis on these topics.

Emerging technologies such as artificial intelligence are poised to enhance vaccine safety monitoring by accelerating data analysis, streamlining established evaluation protocols, and improving the efficiency of expert review processes. While artificial intelligence (AI) can strengthen existing systems, it does not fundamentally change their scientific basis. Clinicians should be aware of both its benefits and the risk of misinformation or exaggerated claims about its role.

Overall, AI represents an incremental but meaningful advancement, enabling faster, more responsive safety surveillance while reinforcing rather than replacing established methods.

No relevant disclosures.